MONISTAT-DERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT-DERM (MONISTAT-DERM).
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Miconazole is primarily metabolized via oxidative N-dealkylation and aromatic hydroxylation, mainly by CYP3A4 and CYP2C9. |
| Excretion | Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections. |
| Protein binding | Miconazole is >90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 20 L/kg, indicating extensive tissue distribution (e.g., skin, lungs, liver). |
| Bioavailability | Topical: Systemic absorption is minimal (<1%), resulting in negligible bioavailability; oral: incomplete (25–30% due to first-pass metabolism), but not used for dermatologic indications. |
| Onset of Action | Topical: Relief from itching and discomfort begins within 24–72 hours; detectable fungistatic levels in stratum corneum within hours of application. |
| Duration of Action | Topical: Sustained antifungal activity persists for at least 24 hours after a single application; clinical cure typically requires 2–4 weeks of treatment. |
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
| Dosage form | LOTION |
| Renal impairment | No specific dose adjustment required for topically applied miconazole. For systemic exposure negligible, no GFR-based modifications needed. |
| Liver impairment | No specific dose adjustments for topical use. Caution in severe hepatic impairment due to potential systemic absorption from extensive application, but no established guidelines. |
| Pediatric use | Children ≥2 years: Apply once daily to affected area for 2-4 weeks. For vaginal use in adolescents: Same as adult dosing. |
| Geriatric use | No specific dose adjustment needed. Use caution with extensive application due to thinner skin and potential increased absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT-DERM (MONISTAT-DERM).
| Breastfeeding | Excretion into human milk is unknown. M/P ratio not established. Consider relevance of maternal dose (topical application with minimal systemic absorption). Use with caution. |
| Teratogenic Risk | In pregnancy category C. Systemic absorption is minimal; however, use in the first trimester is avoided unless clearly necessary. No evidence of teratogenicity in animal studies with topical application. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to miconazole or any component.
| Precautions | Hypersensitivity reactions; avoid occlusive dressings; not for ophthalmic or intravaginal use; potential for hepatotoxicity with systemic absorption. |
Loading safety data…
| None specifically required due to minimal systemic absorption. Monitor for local hypersensitivity or irritation. |
| Fertility Effects | No data on human fertility. Animal studies show no impairment of fertility with topical miconazole. |